ACTEMRA is a prescription medicine used to treat a variety of conditions, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, systemic sclerosis-associated interstitial lung disease, and coronavirus disease 2019.
It works by blocking a substance called IL-6, which is known to cause inflammation.
It is administered as an injection under the skin or as an intravenous infusion.
Common side effects include infections, changes in blood tests, and allergic reactions.
It is important to keep regular visits to the rheumatologist to monitor for any improvements in symptoms.
ACTEMRA is an anti-inflammatory drug used to treat a variety of conditions, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, systemic sclerosis-associated interstitial lung disease, and coronavirus disease 2019. It is important to be aware of the potential risks of serious infections, including tuberculosis, bacterial, invasive fungal, viral, or other opportunistic infections, and to be closely monitored for the development of signs and symptoms of infection. ACTEMRA should be used with caution in patients who may be at increased risk for gastrointestinal perforations, hepatotoxicity, and liver dysfunction.
ACTEMRA® (tocilizumab) Treatment Information for Healthcare Professionals
Tocilizumab (Actemra) is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA).
Tocilizumab (Actemra) - American College of Rheumatology
Tocilizumab is a biologic drug used to treat adults with moderate to severe rheumatoid arthritis, giant cell arteritis, and polyarticular and systemic juvenile idiopathic arthritis. It blocks a substance called IL-6, known to cause inflammation, and is given as an injection once a week or as an IV infusion once a month. Common side effects of tocilizumab include infections, changes in blood tests, and allergic reactions, and it is important to keep regular visits to the rheumatologist to monitor for any improvements in symptoms.
Actemra Information : Tocilizumab - Johns Hopkins Arthritis Center
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, a severe form of arthritis in…
Tocilizumab - Wikipedia
Actemra® (tocilizumab) is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation,…
Actemra: Package Insert / Prescribing Information - Drugs.com
Emergency Use Authorization (EUA) for use of ACTEMRA for the treatment of. COVID-19. 1. The US Food and Drug Administration (FDA) has issued an EUA for the emergency use of…
EUA Treatment Info | ACTEMRA® (tocilizumab)